

**INFORMATION DISCLOSURE STATEMENT**

Applicant	: Hinds, et al.
App. No	: 10/537,635
Filed	: June 2, 2005
For	: BCL-W STRUCTURE AND USES THEREFOR
Examiner	: Unknown
Art Unit	: 1644

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 102 references to be considered by the Examiner. Also enclosed are 102 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: June 27, 2006

By: Raymond D. Smith  
Raymond D. Smith  
Registration No. 55,634  
Agent of Record  
Customer No. 20,995  
(805) 547-5580

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/537,635	
	Filing Date	June 2, 2005	
	First Named Inventor	Mark Gavin Hinds	
	Art Unit	1644	
(Multiple sheets used when necessary)		Examiner	Unknown
SHEET 1 OF 7		Attorney Docket No.	DAVI186.003APC

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	1	WO 97/35971	10/02/1997	AMRAD OPERATIONS PTY. LTD.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	2	SWISS-PROT Accession No. Q92843, 01 November 1997 & Oncogene 13:665-675 (1996)	
	3	GenPept Accession No. BAB23468 & Meth. Enzymol. 303, 19-44 (1999)	
	4	GenPept Accession No. AAH40369, 29 November 2002	
	5	GenPept Accession No. BAB28740, 16 February 2001	
	6	HINDS, M.G., et al., "The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity", EMBO Journal, vol 22 no 7, pp1497-1507, 2003	
	7	DENISOV, A.Y. et al., 2003 "Solution Structure of Human BCL-w", Journal of Biological Chemistry, vol 278 no 23, pp 21124-21128	
	8	ADAMS, J.M., CORY, S. (1992). Oncogene cooperation in leukemogenesis. Cancer Surv. 15, 119-141	
	9	ADAMS, J.M., CORY, S. (1998). The Bcl-2 protein family: arbiters of cell survival. Science 281, 1322-1326.	
	10	ADAMS, J.M., A.W. HARRIS, A. STRASSER, S. OGILVY, AND S. CORY. (1999). Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector. Oncogene 18, 5268	
	11	ADAMS, J.M., CORY, S. (2001). Life-or-death decisions by the Bcl-2 protein family. Trends Biochem. Sci., 26: 61-66	
	12	ANDREWS, M.J.I., TABOR, A.M. (1999). Forming stable helical peptides using natural and artificial amino acids. Tetrahedron 55, 11711-11743.	
	13	ASHKENAZI, A, DIXIT, V.M. (1998). Death receptors: signaling and modulation. Science 281, 1305-1308.	

Examiner Signature	Date Considered
<p><b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/537,635
	Filing Date	June 2, 2005
	First Named Inventor	Mark Gavin Hinds
	Art Unit	1644
(Multiple sheets used when necessary)	Examiner	Unknown
SHEET 2 OF 7	Attorney Docket No.	DAVI186.003APC

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	14	BARTELS, C., XIA, T.H., BILLETER, M., GÜNTERT, P., AND WÜTHRICH, K. (1995). The Program XEASY for Computer-Supported NMR Spectral-Analysis of Biological Macromolecules. J. Biomol. NMR 6, 1-10.	
	15	BORNER, C., MARTINOU, I., MATTMANN, C., IRMLER, M., SCHAEER, E., MARTINOU, J. C., AND TSCHOPP, J. (1994). The protein Bcl-2 alpha does not require membrane attachment, but two conserved domains to suppress apoptosis. J. Cell Biol. 126, 1059-1068.	
	16	BOUILLET, P., METCALF, D., HUANG, D.C.S., TARLINTON, D.M. KAY, T.W., KONTGEN, F., ADAMS, J.M., AND STRASSER, A. (1999). Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286, 1735-1738.	
	17	BROWN JM, WOUTERS BG, (1999). Apoptosis, p53, and tumor cells sensitivity to anticancer agents. Cancer Res. 59, 1391-1399.	
	18	BRÜNGER, A.T., ADAMS, P.D., CLORE, G.M., DELANO, W.L., GROS, P., GROSSE-KUNSTLEVE, R.W., JIANG, J.S., KUSZEWSKI, J., NILGES, M., PANNU, N. S., <i>et al.</i> (1998). Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D. 54, 905-921.	
	19	BURGI R., DAURA Z., MARK A., BELLANDA M., MAMMI S, PEGGION E., VAN GUNSTEREN W. (2001). Folding study of an Aib-rich peptide in DMSO by molecular dynamics simulations. J.Pept. Res. 57, 107-118.	
	20	CHEN-LEVY, Z., NOURSE, J., AND CLEARY, M.L. (1989). The <i>bcl-2</i> candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol. Cell Biol. 9, 701-710.	
	21	CHEN, F, HERSH, B.M., CONRADT, B, ZHOU, Z., REIMER, D., GRUENBAUM, Y., HORVITZ, H.R. (2000). Translocation of <i>C. elegans</i> CED-4 to nuclear membranes during programmed cell death. Science 287, 1485-1489.	
	22	CHEN, L., WRIGHT L.R., CHEN CH, OLIVER SF, WENDER PA, MOCHLY-ROSEN D. (2001). Molecular transporters for peptides: delivery of a cardioprotective ePKC agonist peptide into cells and intact ischemic heart using a transport system. Chem. Biol. 8, 1123-1129.	
	23	CHENG, E.H., WEI, M.C., WEILER, S., FLAVELL, R.A., MAK, T.W., LINDSTEN, T., AND KORSMEYER, S.J. (2001). Bcl-2, Bcl-X <sub>L</sub> sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 8, 705-711.	
	24	CHIN JW, SCHEPARTZ A. (2001). Design and evolution of a miniature Bcl-2 binding protein. Angew. Chem. Int. Ed. 40, 3806-3809.	
	25	CHINNAIYAN AM, O'ROURKE K, LANE BR, DIXIT VM. (1997). Interaction of CED-4 with CED-3 and CED-9: a molecular framework for cell death. Science 275, 1122-1126.	
	26	CHOU, J.J., LI, H., SALVESEN, G.S., YUAN J., AND WAGNER, G. (1999). Solution structure of BID, an intracellular amplifier of apoptotic signaling. Cell 96, 615-624.	
	27	CHRISTOPHER PHELAN J, SKELTON NJ, BRAISTED AC, MCDOWELL RS. (1997). A general method for constraining short peptides to an alpha-Helical conformation. J. Am. Chem. Soc. 119, 455-460.	
	28	CLEARLY, ML, SMITH, SD, SKLAR, J. (1986). Cloning and structural analysis of cDNAs for <i>Bcl-2</i> and a hybrid <i>Bcl-2</i> /immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47, 19-28.	

Examiner Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Multiple sheets used when necessary)</i>	Application No.	10/537,635
	Filing Date	June 2, 2005
	First Named Inventor	Mark Gavin Hinds
	Art Unit	1644
	Examiner	Unknown
SHEET 3 OF 7	Attorney Docket No.	DAVI186.003APC

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	29	CONUS, S. ROSSE, T. BORNER C. (2000). Failure of Bcl-2 family members to interact with Apaf-1 in normal and apoptotic cells. <i>Cell Death Differ.</i> 7, 947-954.	
	30	CORY, S., AND ADAMS, J.M. (2002). The Bcl-2 family: Regulators of the cellular life-or-death switch. <i>Nature Reviews Cancer.</i> 2, 647-677.	
	31	DAY, C.L., DUPONT, C., LACKMANN, M., VAUX, D.L. AND HINDS, M.G. (1999). Solution structure and mutagenesis of the caspase recruitment domain (CARD) from Apaf-1. <i>Cell Death Differ.</i> 6, 1125-1132.	
	32	DEL MAR MARTINEZ-SENAC, M., CORBALAN-GARCIA, S. AND GOMEZ-FERNANDEZ, J.C. (2000). Study of the secondary structure of the C-terminal domain of the antiapoptotic protein Bcl-2 and its interaction with model membranes. <i>Biochemistry</i> 39, 7744-7752.	
	33	FAIRLIE DP, WEST ML, WONG AK. (1998). Towards protein surface mimetics. <i>Curr. Med. Chem.</i> 5, 29-62.	
	34	FISHER, D.E. (1994). Apoptosis in cancer therapy: crossing the threshold. <i>Cell</i> 78, 539-542.	
	35	GIBSON, L., HOLMGREEN, S.P., HUANG, D.C.S., BERNARD, O., COPELAND, N.G., JENKINS, N.A., SUTHERLAND, G.R., BAKER, E., ADAMS, J.M., AND CORY, S. (1996). Bcl-w, a novel member of the Bcl-2 family, promotes cell survival. <i>Oncogene</i> 13, 665-675.	
	36	GONZALEZ-GARCIA, M., PEREZ-BALLESTERO, R., DING, L., DUAN, L., BOISE, L.H., THOMPSON, C.B. AND NUÑEZ, G. (1994). <i>Bcl-x<sub>L</sub></i> is the major <i>bcl-x</i> mRNA form expressed during murine development and its product localizes to mitochondria. <i>Development</i> 120, 3033-3042.	
	37	GRAS-MASSÉ H. (2001). Single-chain lipopeptide vaccines for the induction of virus-specific cytotoxic T cell responses in randomly selected populations. <i>Mol. Immunol.</i> 38, 423-431.	
	38	GÜNTERT, P., MUMENTHALER, C., AND WÜTHRICH, K. (1997). Torsion angle dynamics for NMR structure calculation with the new program DYANA. <i>J. Mol. Biol.</i> 273, 283-298.	
	39	HAN J, FLEMINGTON C. HOUGHTON AB, GU Z, ZAMBETTI GP, LUTZ RJ, ZHU L, CHITTENDEN T. (2001). Expression of <i>bbc3</i> , a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. <i>Proc. Natl. Acad. Sci. USA</i> 98, 11318-11323.	
	40	HAUSMANN, G., O'REILLY, L.A., VAN DRIEL, R., BEAUMONT, J.G., STRASSER, A., ADAMS, J.M., AND HUANG, D.C.S. (2000). Pro-apoptotic apoptosis protease-activating Factor 1 (apaf-1) has a cytoplasmic localization distinct from Bcl-2 or Bcl-x <sub>L</sub> . <i>J. Cell Biol.</i> 149, 623-634.	
	41	HARAGUCHI M, TORII S, MATSUZAWA S, XIE Z, KITADA S, KRAJEWSKI S, YOSHIDA H, MAK TW, REED JC. (2000). Apoptotic protease activating factor 1(Apaf-1)-independent cell death suppression by Bcl-2. <i>J. Exp. Med.</i> 191, 1709-1720.	
	42	HOLINGER EP, CHITTENDEN T, LUTZ RJ. (1999). Bak BH3 peptides antagonize Bcl-x <sub>L</sub> function and induce apoptosis through cytochrome c-independent activation of caspases. <i>J. Biol. Chem.</i> 274, 13298-13304	
	43	HSU, Y.T., WOLTER, K.G., AND YOULE, R.J. (1997). Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. <i>Proc. Natl. Acad. Sci. USA</i> 94, 3668-3672.	
	44	HUANG, D.C.S., ADAMS, J.M., AND CORY, S. (1998). The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. <i>EMBO J.</i> 17, 1029-1039.	

Examiner Signature	Date Considered
<p><b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/537,635
	Filing Date	June 2, 2005
	First Named Inventor	Mark Gavin Hinds
	Art Unit	1644
(Multiple sheets used when necessary)	Examiner	Unknown
SHEET 4 OF 7	Attorney Docket No.	DAVI186.003APC

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	45	HUANG D.C.S et al. 2000 "BH3-only proteins- Essential Initiators of apoptotic cell death" <i>Cell</i> 103:839-842.	
	46	HUANG Q et al. 2002 "Solution structure of a Bcl-2 homolog from Kaposi sarcoma virus" <i>Proc Natl Acad Sci U.S. A.</i> 99:3428-3433.	
	47	JUDICE J.K. et al. 1997 "Inhibition of HIV type 1 infectivity by constrained $\alpha$ -helical peptides: Implications for the viral fusion mechanism" <i>Proc Natl Acad Sci USA</i> 94:13426-13430.	
	48	KASHER R. et al. 1999 "Miniaturized proteins: the backbone cyclic proteinomimetic approach" <i>J Mol Biol</i> 292:421-429.	
	49	KLEIGER, G., GROTHE, R., MALLICK, P., AND EISENBERG, D. (2002). GXXXG and AXXXA: common $\alpha$ -helical interaction motifs in proteins, particularly in extremophiles. <i>Biochemistry</i> 41, 5990-5997.	
	50	KORADI, R., BILLETER, M., AND WÜTHRICH, K. (1996). MOLMOL: A program for display and analysis of macromolecular structures. <i>J. Mol. Graph.</i> 14, 51-55.	
	51	KRAJEWSKI, S., TANAKA, S., TAKAYAMA, S., SCHIBLER, M.J., FENTON, W., AND REED, J.C. (1993). Investigation of the subcellular distribution of the Bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. <i>Cancer Res.</i> 53, 4701-4714.	
	52	LACKMANN, M., MANN, R.J., KRAVETS, L., SMITH, F.M., BUCCI, T.A., MAXWELL, K.F., HOWLETT, G.J., OLSSON, J.E., VANDEN BOX, T., CERRETTI, D.P., AND BOYD, A.W. (1997). Ligand for EPH-related kinase (LERK) 7 is the preferred high affinity ligand for the HEK receptor. <i>J. Biol. Chem.</i> 272, 16521-16530.	
	53	LANE DP. (1992). P53, guardian of the genome. <i>Nature</i> 358, 15-16.	
	54	LAPIDOT, T., Y. FAJERMAN, AND O. KOLLET. (1997). Immune-deficient SCID and NOD/SCID mice models as functional assays for studying normal and malignant human hematopoiesis. <i>Journal of Molecular Medicine</i> 75, 664.	
	55	LASKOWSKI, R.A., RULLMANN, J.A.C., MACARTHUR, M.W., KAPTEIN, R., AND THORNTON, J.M. (1996). AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR. <i>J. Biomol. NMR</i> 8, 477-786.	
	56	LINGE, J.P., AND NILGES, M. (1999). Influence of non-bonded parameters on the quality of NMR structures: A new force field for NMR structure calculation. <i>J. Biomol. NMR</i> 13, 51-59.	
	57	LITHGOW, T., VAN DRIEL, R., BETRAM, J.F., AND STRASSER, A. (1994). The protein product of the oncogene Bcl-2 is a component of the nuclear envelope, the endoplasmic reticulum, and the outer mitochondrial membrane. <i>Cell Growth Differ.</i> 5, 411-417.	
	58	LOWE SW, SCHMITT EM, SMITH SW, OSBORNE BA, (1993). Lacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. <i>Nature</i> 362, 847-849.	
	59	LU, G.G. (2000). TOP: a new method for protein structure comparisons and similarity searches. <i>J. Appl. Cryst.</i> 33, 176-183.	
	60	MALMQVIST, M. (1999) BIACORE: an affinity biosensor system for characterization of biomolecular interactions. <i>Biochem Soc Trans.</i> 27, 335-340.	

Examiner Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/537,635
	Filing Date	June 2, 2005
	First Named Inventor	Mark Gavin Hinds
	Art Unit	1644
(Multiple sheets used when necessary)	Examiner	Unknown
SHEET 5 OF 7	Attorney Docket No.	DA VII86.003APC

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	61	MARSDEN, V.S., O'CONNOR, L., O'REILLY, L.A., SILKE, J., METCALF, D., EKERT, P.G., HUANG, D.C.S., CECCONI, F., KUIDA, K., TOMASELLI, K.J., ROY, S., NICHOLSON, D.W., VAUX, D.L., BOUILLET, P., ADAMS, J.M. AND STRASSER, A. (2002) Apoptosis initiated by Bcl-2 regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. <i>Nature</i> , 419, 634-637.	
	62	MCDONNELL, J.M., FUSHMAN, D., MILLIMAN, C.L., KORSMEYER, S.J., AND COWBURN, D. (1999). Solution structure of the proapoptotic molecule BID: a structural basis for apoptotic agonists and antagonists. <i>Cell</i> 96, 625-634.	
	63	MORIISHI, K., HUGANG, D.C.S., CORY, S., AND ADAMS, J.M. (1999). Bcl-2 family members do not inhibit apoptosis by binding the caspase activator Apaf-1. <i>Proc. Natl. Acad. Sci. USA</i> 96, 9683-9688.	
	64	MUCHMORE, S.W. et al. 1996 "X-ray and NMR structure of human Bcl-XL, an inhibitor of programmed cell death" <i>Nature</i> 381:335-341.	
	65	NAKANO K, WOUSDEN KH. (2001). <i>PUMA</i> , a novel proapoptotic gene, is induced by p53. <i>Mol. Cell</i> 7, 683-694.	
	66	NECHUSHTAN, A., SMITH, C.L., HSU, Y.T., AND YOULE, R.J. (1999). Conformation of the Bax C-terminus regulates subcellular location and cell death. <i>EMBO J.</i> 18, 2330-2341.	
	67	NECHUSHTAN, A., SMITH, C.L., LAMENSDORF, I., YOON, S.H., AND YOULE, R.J. (2001). Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. <i>J. Cell Biol.</i> 153, 1265-1276.	
	68	O'CONNOR, L., STRASSER, A., O'REILLY, L. A., HAUSMANN, G., ADAMS, J.M., CORY, S., AND HUANG, D.C.S. (1998). Bim: a novel member of the Bcl-2 family that promotes apoptosis. <i>EMBO J.</i> 17, 384-395.	
	69	ODA, E., OHKI, R., MURASAWA, H., NEMOTO, J., SHIBUE, T., YAMASHITA, T., TOKINO, T., TANIGUCHI, T., TANAKA, N. (2000). Noxa, A BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. <i>Science</i> 288, 1053-1058.	
	70	O'REILLY, L. A., PRINT, C., HAUSMANN, G., MORIISHI, K., CORY, S., HUANG, D.C.S., AND STRASSER, A. (2001). Tissue expression and subcellular localization of the pro-survival molecule Bcl-w. <i>Cell Death Differ.</i> 8, 486-494.	
	71	PETROS, A.M., MEDEK, A., NETTESHEIM, D.G., KIM, D.H., YOON, H.S., SWIFT, K., MATAYOSHI, E.D., OLTERSDORF, T., AND FESIK, S.W. (2001). Solution structure of the antiapoptotic protein Bcl-2. <i>Proc. Natl. Acad. Sci. USA</i> 98, 3012-3017.	
	72	PETROS, A.M., NETTESHEIM, D.G., WANG, Y., OLEJNICZAK, E.T., MEADOWS, R.P., MACK, J., SWIFT, K., MATAYOSHI, E.D., ZHANG, H., THOMPSON, C.B., AND FESIK, S.W. (2000). Rationale for Bcl-x <sub>L</sub> /Bad peptide complex formation from structure, mutagenesis, and biophysical studies. <i>Protein Sci.</i> 9, 2528-2534.	
	73	PRINT, C.G., LOVELAND, K.L., GIBSON, L., MEEHAN, T., STYLIANOU, A., WREFORD, N., DE KRESTER, D., METCALF, D., KONTGEN, F., ADAMS, J.M., AND CORY S. (1998). Apoptosis regulator Bcl-w is essential for spermatogenesis but appears otherwise redundant. <i>Proc. Natl. Acad. Sci. USA</i> 95, 12424-12431.	
	74	PUTHALAKATH H, HUANG DCS, O'REILLY LA, KING SM, STRASSER A. (1999). The proapoptotic activity of the Bcl2 family member Bim is regulated by interaction with the dynein motor complex. <i>Mol. Cell</i> 3, 287-296.	

Examiner Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/537,635
	Filing Date	June 2, 2005
	First Named Inventor	Mark Gavin Hinds
	Art Unit	1644
(Multiple sheets used when necessary)	Examiner	Unknown
SHEET 6 OF 7	Attorney Docket No.	DAVI186.003APC

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	75	PUTHALAKATH H, VILLUNGER A, O'REILLY LA, BEAUMONT JG, COULTAS L, CHENEY RE, HUANG DCS, STRASSER A. (2001). Bmf: a pro-apoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. <i>Science</i> 293, 1829-1832.	
	76	SATTTLER, M., LIANG, H., NETTESHEIM, D., MEADOWS, R.P., HARLAN, J.E., EBERSTADT, M., YOON, H.S., SHUKER, S.B., CHANG, B.S., MINN, A.J., THOMPSON, C.B., AND FESIK, S.W. (1997). Structure of Bcl-x <sub>L</sub> -Bak peptide complex: recognition between regulators of apoptosis. <i>Science</i> 275, 983-986.	
	77	SATTTLER, M., SCHLEUCHER, J., AND GRIESINGER, C. (1999). Heteronuclear multidimensional NMR experiments for the structure determination of proteins in solution employing pulsed field gradients. <i>Prog. Nucl. Magn. Reson. Spectrosc.</i> 34, 93-158.	
	78	SCHAFMEISTER CE, PO J, VERDINE GL. (2000). An All-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. <i>J. Am. Chem. Soc.</i> 122,5891-5892.	
	79	SCHIMMER AD, HEDLEY DW, CHOW S, PHAM NA, CHAKRABARTTY A, BOUCHARD D, MAK TW, TRUS MR, MINDEN MD. (2001). The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2. <i>Cell Death Differ</i> 8, 725-733.	
	80	SCHOLTZ JM, BALDWIN RL. (1992). The mechanism of $\alpha$ -helix formation by peptides. <i>Annu. Rev. Biophys. Biomol. Struct.</i> 21, 95-118.	
	81	SPECTOR MS, DESNOYERS S, HOEPPNER DJ, HENGARTNER MO. (1997). Interaction between the <i>C. elegans</i> cell-death regulators CED-9 and CED-4. <i>Nature</i> 385, 653-665.	
	82	STOCKMAN, B.J. AND DALVIT, C. (2002) NMR Screening in drug discovery and drug design. <i>Prog. NMR Spectrosc.</i> 41, 187-231.	
	83	SENES, A., GERSTEIN, M. AND ENGELMAN, D.M. (2000). Statistical analysis of amino acid patters in transmembrane helices: the GxxxG motif occurs frequently and in association with beta-branched residues at neighboring positions. <i>J. Mol. Biol.</i> 296, 921-936.	
	84	STRASSER, A., HARRIS, AW, BATH, ML, CORY, S. (1990). Novel primitive lymphoid tumours induced in transgeneic mice by cooperation between <i>myc</i> and <i>Bcl-2</i> . <i>Nature</i> 348, 331-333.	
	85	STRASSER, A., A.G. ELEFANTY, A.W. HARRIS, AND S. CORY. (1996). Progenitor tumours from Em- <i>bcl-2-myc</i> transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival. <i>EMBO Journal</i> 15, 3823.	
	86	STRASSER, A., HARRIS AW, JACKS T., COR S. (1994) DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. <i>Cell</i> 79, 329-339.	
	87	STRASSER, A., O'CONNER, L., DIXIT VM. (2000). Apoptosis signaling. <i>Annu. Rev. Biochem</i> 69, 217-245.	
	88	SUZUKI, M., YOULE, R.J., AND TJANDRA, N. (2000). Structure of Bax: coregulation of dimer formation and intracellular localization. <i>Cell</i> 103, 645-654.	
	89	THOMPSON, C.B. (1995) Apoptosis in the pathogenesis and treatment of disease. <i>Science</i> 267, 1456-1462.	
	90	THORNBERRY, NA, LAZEBNIK, Y. (1998). Caspases: enemies within. <i>Science</i> 281, 1312-1316.	
	91	TSUJIMOTO, Y, COSSMAN, J., JAFFE, E. CROCE CM. (1985). Involvement of the <i>Bcl-2</i> gene in human follicular lymphoma. <i>Science</i> 228, 1440-1443.	

Examiner Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/537,635
	Filing Date	June 2, 2005
	First Named Inventor	Mark Gavin Hinds
	Art Unit	1644
(Multiple sheets used when necessary)	Examiner	Unknown
SHEET 7 OF 7	Attorney Docket No.	DA VII186.003APC

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	92	VAUX, D.L., CORY S, ADAMS JM. (1998). <i>Bcl-2</i> gene promotes haemopoietic cell survival and cooperates with <i>c-myc</i> to immortalize pre-B cells. <i>Nature</i> 335, 440-442.	
	93	VAUX, D.L., AND KORSMEYER, S.J. (1999). Cell death in development. <i>Cell</i> 96, 245-254.	
	94	VOUSDEN, KH. (2000). P53: death star. <i>Cell</i> 103, 691-694.	
	95	VUISTER, G.W., AND BAX, A. (1993). Quantitative J Correlation: A New Approach For Measuring Homonuclear Three-Bond J(H <sup>N</sup> H <sup>α</sup> ) Coupling Constants in <sup>15</sup> N-Enriched Proteins. <i>J. Am. Chem. Soc.</i> 115, 7772-7777.	
	96	WANG, JL, ZHANG, ZJ, CHOSKI, S, SHAN, S, LU, Z, CROCE, CM, ALNEMRI, ES, KORNGOLD, R, HUANG, Z. (2000). Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. <i>Cancer Res.</i> 60., 1498-1502.	
	97	WILSON-ANNAN, J., O'REILLY, L.A., CRAWFORD, S.A., HAUSMANN, G., BEAUMONT J.G., PARMA, L.P., CHEN, L., LACKMANN, M., LITHGOW, T., HINDS, M.G., DAY, C.L., ADAMS, J.M., HUANG, D.C. (2003). Proapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activity. <i>J Cell Biol.</i> 162:877-887.	
	98	WISHART, D.S., BIGAM, C.G., YAO, J., ABILDGAARD, F., DYSON, H.J., OLDFIELD, E., MARKLEY, J.L., AND SYKES, B.D. (1995). <sup>1</sup> H, <sup>13</sup> C and <sup>15</sup> N Chemical Shift Referencing in Biomolecular NMR. <i>J. Biomol. NMR</i> 6, 135-140.	
	99	WU DY, WALLEN HD, NUÑEZ G. (1997). Interaction and regulation of subcellular localization of CED-4 by CED-9. <i>Science</i> 275, 1126-1129.	
	100	YANG X, CHANG HY, BALTIMORE D. (1998). Essential role of CED-4 oligomerization in CED-3 activation and apoptosis. <i>Science</i> 281, 1355-1357.	
	101	YU J, ZHANG L, HWANG PM, KINZLER KW, VOGELSTEIN B. (2001). PUMA induces the rapid apoptosis of colorectal cancer cells. <i>Mol. Cell</i> 7, 673-682.	
	102	ZONG, W. X. LINDSTEN, T., ROSS, A.J., MACGREGOR, G.R., AND THOMPSON, C.B. (2001). BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. <i>Genes Dev.</i> 15, 1481-1486.	

1892925:cbm  
082605

Examiner Signature	Date Considered
<p><b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.